The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC – ESMO

ESMO (European Society for Medical Oncology) shared on LinkedIn:

“Data from two presentations at ESMOGI24 highlight the clinical utility of liquid biopsies detecting circulating tumor DNA (ctDNA) in guiding treatment for patients with Metastatic Colorectal Cancer (mCRC) and providing prognostic information post-surgery for patients with stage 3 colon cancer.

To learn more about this topic, read the analysis from Pashtoon Kasi in the latest ESMO Daily Reporter article.”

Source: ESMO/LinkedIn